Equities analysts expect Ra Pharmaceuticals Inc (NASDAQ:RARX) to report earnings per share (EPS) of ($0.52) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Ra Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.54) and the highest estimate coming in at ($0.51). Ra Pharmaceuticals reported earnings per share of ($0.68) in the same quarter last year, which would indicate a positive year-over-year growth rate of 23.5%. The business is scheduled to announce its next quarterly earnings report on Thursday, November 8th.
According to Zacks, analysts expect that Ra Pharmaceuticals will report full year earnings of ($2.14) per share for the current financial year, with EPS estimates ranging from ($2.22) to ($2.07). For the next fiscal year, analysts forecast that the company will post earnings of ($2.11) per share, with EPS estimates ranging from ($2.28) to ($1.95). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Ra Pharmaceuticals.
Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.01.
Several brokerages have recently issued reports on RARX. ValuEngine raised Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Zacks Investment Research cut Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Credit Suisse Group set a $25.00 price objective on Ra Pharmaceuticals and gave the company a “buy” rating in a report on Friday. BidaskClub cut Ra Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, October 5th. Finally, Raymond James raised Ra Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $28.00 price target for the company in a report on Wednesday, October 10th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $20.60.
Shares of RARX stock opened at $16.64 on Friday. The stock has a market capitalization of $538.14 million, a PE ratio of -6.90 and a beta of 1.42. Ra Pharmaceuticals has a 52-week low of $4.78 and a 52-week high of $19.43.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in Ra Pharmaceuticals by 33.5% in the 2nd quarter. BlackRock Inc. now owns 1,537,331 shares of the company’s stock worth $15,297,000 after purchasing an additional 385,587 shares during the period. First Manhattan Co. grew its position in Ra Pharmaceuticals by 38.1% in the third quarter. First Manhattan Co. now owns 1,073,906 shares of the company’s stock worth $19,426,000 after acquiring an additional 296,419 shares during the period. Millennium Management LLC grew its position in Ra Pharmaceuticals by 50.9% in the first quarter. Millennium Management LLC now owns 671,262 shares of the company’s stock worth $3,564,000 after acquiring an additional 226,565 shares during the period. JPMorgan Chase & Co. grew its position in Ra Pharmaceuticals by 59.5% in the first quarter. JPMorgan Chase & Co. now owns 436,091 shares of the company’s stock worth $2,315,000 after acquiring an additional 162,714 shares during the period. Finally, Citadel Advisors LLC grew its position in Ra Pharmaceuticals by 5.7% in the second quarter. Citadel Advisors LLC now owns 349,201 shares of the company’s stock worth $3,475,000 after acquiring an additional 18,754 shares during the period. 73.32% of the stock is owned by institutional investors.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Recommended Story: Do Tariffs Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.